Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00252759
Status:
COMPLETED
Last Update Posted:
2011-01-28
First Post:
2005-11-14
Brief Title:
Iressa Case Control Study in Japan
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Nested Case-control Study to Determine the Relative Risk of and Risk Factors for Interstitial Lung Disease in a Cohort of NSCLC Patients Treated With and Without Gefitinib
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this study are
To estimate the relative risk of ILD in advancedrecurrence NSCLC patients treated with gefitinib as compared to other chemotherapy treatment and to assess the risk factors for ILD in advancedrecurrence NSCLC patients undergoing treatment
To provide an estimate of the incidence of ILD in a group of advancedrecurrence NSCLC patients undergoing treatment
To estimate the relative risk of ILD in advancedrecurrence NSCLC patients treated with gefitinib as compared to other chemotherapy treatment and to assess the risk factors for ILD in advancedrecurrence NSCLC patients undergoing treatment
To provide an estimate of the incidence of ILD in a group of advancedrecurrence NSCLC patients undergoing treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| V-15-33 | None | None | None |
| OZV1533 | None | None | None |